SAINT HELIER (dpa-AFX) - Shire plc (SHPGY, SHP.L) announced that it will present scientific data from one oral and 16 poster presentations at the American Psychiatric Association 165th Annual Meeting to be held May 5-9.
The data being presented represent Shire's ongoing commitment to the clinical research of Vyvanse (lisdexamfetamine dimesylate) Capsules, or CII and INTUNIV (guanfacine) Extended-Release Tablets, its approved treatments for ADHD.
In addition to ADHD research, data being presented will focus on investigational research in other psychiatric and neurobehavioral disorders, such as major depressive disorder and negative symptoms of schizophrenia. Shire also will present health economic outcomes research, as part of the company's efforts to develop cost-effective treatments for ADHD, Shire said.
Copyright RTT News/dpa-AFX
© 2012 AFX News
